Loading...
0.81
HR for Global Health Deterioration
20.4 mo
Median Follow-up
Maintained
Overall HRQOL Status
Study Design & Methods
Randomized comparison of Ribociclib + Fulvestrant vs Placebo + Fulvestrant in HR+/HER2- advanced breast cancer.
Baseline EORTC QLQ-C30 Scores
Comparison of mean baseline scores across groups. Higher Global Health is better; Lower Fatigue/Pain is better.
Time to Deterioration (Hazard Ratios)
Hazard Ratios < 1.0 favor Ribociclib. Error bars represent 95% CI.
Baseline Symptom Burden
Comparison of Fatigue vs Pain scores at baseline. Lower scores indicate less symptom burden.
Risk Reduction Magnitude
Percentage reduction in risk of deterioration (1 - HR) for Ribociclib vs Placebo.
Study Population (2:1 Randomization)
Distribution of patients across treatment arms.
Appendix: Raw Data & Provenance
| Metric | Group/Comparison | Value | Source |
|---|